Advancing a Potent Inhibitor of SARS-CoV-2 3CL Protease into Clinical Trials

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:1 publications

Grant number: 172645

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2020
  • Known Financial Commitments (USD)

    $678,177
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principle Investigator

    Pending
  • Research Location

    Canada, Americas
  • Lead Research Institution

    University of Alberta Medical Microbiology and Immunology
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The coronavirus, SARS-CoV-2, has caused COVID-19, a disease that is currently pandemic. The drug GC376 targets an enzyme in the virus that stops its replication. This drug has been used successfully to treat a fatal disease in cats known as Feline Infectious Peritonitis (FIP). FIP is caused by a coronavirus similar to the virus causing COVID-19. This study will move GC376 into phase I human trials on the path to bringing this compound to the benefit of patients with COVID-19.

Publicationslinked via Europe PMC

Last Updated:39 minutes ago

View all publications at Europe PMC

Fast spark discharge-laser-induced breakdown spectroscopy method for rice botanic origin determination.